Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Cano, A (Author) Other; Ettcheto, M (Author) Other; Espina, M (Author) Other; Auladell, C (Author) Other; Folch, J (Author) Other; Kuhne, BA (Author) Other; Barenys, M (Author) Other; Sanchez Lopez, E (Author) Other; Souto, EB (Author) Other; Garcia, ML (Author) Other; Turowski, P (Author) Other; Camins, A (Author) Other

Journal

Title: Nanomedicine

Vol. 16

Pages: 19-35

ISSN: 1743-5889

Publisher: Future Medicine Ltd.

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-00T-C0G

DOI: 10.2217/nnm-2020-0239

Abstract (EN): Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntington's disease (HD)-like symptoms in mice. Materials & methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases. Lay abstract Huntington's disease (HD) is a debilitating neurodegenerative disease that affects around 5-10/100,000 individuals in developed countries. It is caused by genetic alterations in the huntingtin (htt) gene. Efforts are being made to find treatments which will correct the genetic alterations or their consequences; however, none of these options are yet available to patients. Thus, therapies that improve the symptoms of HD, which include motor dysfunction and a wide range of behavioral disturbances, are also needed. Epigallocatechin-3-gallate (EGCG) is a powerful compound extracted from the green tea plant that may possess beneficial effects for HD patients, but whose therapeutic success is limited because of its chemical instability. In this study, we show that encasing EGCG in nano-sized capsules makes it much more efficient in reducing motor deficits and depression-like behavior in a mouse model of HD-like neurodegeneration. Importantly, behavioral improvement was also associated with a reduction of nerve cell damage. These results, together with previous findings using nano-encapsulated EGCG in mouse models of Alzheimer's disease and epilepsy, highlight their potential effectiveness for treating the symptoms of neurodegenerative diseases. [GRAPHICS] .

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 17